The more muscle mass is lost during hospitalization for COVID-19, the greater the likelihood of developing persistent symptoms of the disease, such as weakness and so-called long COVID, which can ...

Dyne Therapeutics is developing treatments for genetically driven muscle diseases, focusing on Myotonic Dystrophy Type 1 (DM1) and Duchenne Muscular Dystrophy (DMD). Their lead candidate, DYNE-101, is ...

For decades, treatment of peripheral artery disease has focused almost exclusively on restoring blood flow. Now, new research ...

Myasthenia gravis (MG) does not have stages but classes. These classes describe the muscles the condition affects and the severity of muscle weakness, which can influence the treatments a doctor may ...